Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Dyne Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- +12 vs. Q2 2022
- Shares held
- 44.6M
- −2.12M (−4.5%) vs. Q2 2022
- Total value
- $565.8M
- +$245.1M (+76.4%) vs. Q2 2022
- New holders
- 26
- 32 more added
- Sold out
- 14
- 28 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DYN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 245 | $4.23B |
| Q1 2026 | 228 | $3.40B |
| Q4 2025 | 233 | $3.48B |
| Q3 2025 | 207 | $1.97B |
| Q2 2025 | 198 | $1.22B |
| Q1 2025 | 205 | $1.29B |
| Q4 2024 | 200 | $2.63B |
| Q3 2024 | 200 | $4.03B |
| Q2 2024 | 193 | $3.92B |
| Q1 2024 | 169 | $2.71B |
| Q4 2023 | 124 | $930.0M |
| Q3 2023 | 114 | $536.6M |
| Q2 2023 | 118 | $665.9M |
| Q1 2023 | 127 | $628.7M |
| Q4 2022 | 113 | $576.2M |
| Q3 2022 | 102 | $565.8M |
| Q2 2022 | 90 | $320.7M |
| Q1 2022 | 94 | $456.6M |
| Q4 2021 | 93 | $568.3M |
| Q3 2021 | 83 | $572.8M |
| Q2 2021 | 76 | $753.4M |
| Q1 2021 | 75 | $533.3M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Dyne Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Asset Management LLC | 4,951,303 | $62.9M | 23.95% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $113.5M | 12.52% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 0 | $0 | 0.00% | −2,805,045−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −666,997−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −215,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −98,866−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −41,304−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −36,984−100.0% | Sold out |
| Summit Rock Advisors, LP | 0 | $0 | 0.00% | −34,887−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −15,996−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −2,100−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −347−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −132−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −37−100.0% | Sold out |